ClinicalTrials.gg
CompletedNCT01814878Updated Jun 20, 2013Results posted

A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain

A Phase 3 interventional study of Tramadol HCl/Acetaminophen ER and Tramadol HCl/Acetaminophen IR in Pain, Postoperative, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-06-20.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
25 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing tramadol in Pain, Postoperative — 3 open to participants now, 5 under way, none of them phase 3. Tramadol · Pain, Postoperative.

Enrollment
7th of 34
320 · median 93
Started
2009
with 2 others
Phase 3
3 of 34
none open now
Registered
9th of 34
by date

Among the 34 studies testing tramadol in Pain, Postoperative, this one is the 7th largest by enrollment, is one of 3 that started in 2009, is one of 3 in phase 3, and was the 9th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 34 studies testing tramadol in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 25 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing tramadol in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of extended release (ER) tramadol hydrochloride (HCl)/acetaminophen with immediate release (IR) tramadol HCl/acetaminophen in participants with moderate to severe (very serious, life threatening) postoperative pain.

Read the detailed description

This study is a randomized (study drug assigned by chance), multicenter (when more than 1 hospital or medical school team work on a medical research study), active-controlled, parallel group (each group of participants will be treated at the same time), double-blind (neither physician nor participant knows the treatment that the participant receives) study. The duration of the treatment will be 2 days and will be conducted in 4 periods: screening period (from 33 to 2 days before study drug administration to the first surgical incision), surgical period (to 1 day before study drug administration), qualification period (1 day) and double-blind treatment period (1 to 2 days). Participants will be randomly assigned to 2 groups: study drug treatment group (ER) and comparator treatment group (IR). Participants will be administered 2 tablets of ER tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) along with 2 tablets of placebo matching to IR tramadol HCl/acetaminophen in study drug treatment group; and 2 tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) along with 2 tablets of placebo matching to ER tramadol HCl/acetaminophen in comparator treatment group respectively at 0, 12, 24 and 36 hours. Participants will also be administered 2 tablets of placebo matching to IR tramadol HCl/acetaminophen in study drug treatment group; and 2 tablets of IR tramadol HCl/acetaminophen in comparator treatment group respectively at 6, 18, 30 and 42 hours. Participants will be administered investigational product at 6-hour interval from the time of the first investigational product administration over 48 hours. Efficacy will be assessed using 11-point numeric rating scale (NRS). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Pain, Postoperative
  • Tramadol Hydrochloride
  • Acetaminophen
  • Ultracet
04

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are scheduled to have standard primary (non-revision) unilateral (having to do with only 1 side of a structure) total knee replacement arthroplasty (TKRA-surgery to fix a joint) for non-inflammatory (no swelling, redness, and pain in tissues caused by injury or damage) degenerative joint disease (NIDJD)
  • Participants who are capable of oral (having to do with the mouth) intake
  • Women must be: (for at least 1 year), surgically sterile, abstinent (not having sexual intercourse), or practicing a highly effective method of before participation in the study and who agree to continue to use the same method of birth control throughout the study in cases of women of
  • Male participants must practice contraception, and must agree not to donate his sperms for 1 month after the last dose of study drug
  • Participants who will complain of baseline pain of intensity of greater than or equal to 4 on 11-point numeric rating scale (NRS) measured within 1 hour prior to randomization (study drug assigned by chance) and a maximum of 6 hours after discontinuation of participant controlled analgesia (PCA) after at least 12 hours of application following TKRA

Exclusion criteria

Exclusion Criteria:

  • Participants with Illness history (severe [very serious, life threatening] hepatic [having to do with the liver] failure, severe renal [having to do with the kidney] failure; severe respiratory depression; risk for mental fog with head injury or brain lesions [abnormal area of tissue, such as a wound, sore, rash, or boil]; digestive ulcer [sore], severe blood abnormalities; severe cardiac insufficiency; aspirin asthma [asthmatic attack-breathing disorder in which there is a wheezing and difficulty in breathing; caused by non-steroidal anti-inflammatory drugs] or history of aspirin asthma; history of epilepsy [seizure disorder]; rheumatism, significant psychiatric disorder or taking antipsychotic drugs for psychiatric treatment)
  • Administration of disallowed therapy such as: administration of oral, patch, injection or local analgesics (drug used to control pain) acting centrally (the brain and the spinal cord) or peripherally (not central) before study drug administration after completion of PCA application, surgery is conducted simultaneously in addition to TKRA, administration of monoamine oxidase (MAO) inhibitors or discontinuation of the administration within 2 weeks, tricyclic antidepressants that may increase the seizure (sudden, uncontrolled muscle spasms and loss of consciousness resulting from abnormal brain function) risk when concomitantly (given at the same time) administered, neuroleptics, or drugs that may lower the seizure threshold, use of sedatives (a medication to calm or make less anxious) other than that used for general anesthesia (loss of sensation or feeling) during surgery
  • Participants who used any study drug or medical device within 30 days before the start of the treatment
  • Participants requiring postoperative intensive care unit (ICU) care
  • Participants having to tramadol or acetaminophen
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Tramadol Hydrochloride/Acetaminophen ER

    Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram \[mg\])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.

    Drug: Tramadol HCl/Acetaminophen ER

  • Active comparator
    Tramadol HCl/Acetaminophen IR

    Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.

    Drug: Tramadol HCl/Acetaminophen IR

Interventions

  • DrugTramadol HCl/Acetaminophen ER

    Drug pages: Tramadol · Acetaminophen

    2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours

    Also known as: Ultracet

  • DrugTramadol HCl/Acetaminophen IR

    Drug pages: Tramadol · Acetaminophen

    2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours

    Also known as: Ultracet

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference (SPID) at Hour 48

    The SPID is time-weighted sum of all observations of pain intensity difference (PID) collected at each measurement time point from Baseline to 48 hours. PID: Baseline pain intensity (PI) minus current PI; PI was assessed using 11-point numeric rating scale (NRS, 0=no pain to 10=worst pain imaginable). PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score for SPID at 48 hours (SPID48) ranges from -144 (worst) to 144 (best).

    Time frame: Hour 48

Secondary outcomes

  1. Sum of Pain Intensity Difference (SPID) at Hour 6, 12 and 24

    The SPID is time-weighted sum of all observations of PID collected at each measurement time point from Baseline to 24 hours. PID: Baseline PI minus current PI; PI was assessed using 11-point NRS, 0=no pain to 10=worst pain imaginable. PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score ranges from -18 (worst) to 18 (best) for SPID6, -36 (worst) to 36 (best) for SPID12 and -72 (worst) to 72 (best) for SPID24.

    Time frame: Hour 6, 12, 24

  2. Total Pain Relief (TOTPAR) Score

    Pain relief was measured on a 5-point categorical scale of 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). TOTPAR was calculated as the time-weighted sum over all pain relief up to 48 hours. Total score ranges from 0 (worst) to 24 (best) for TOTPAR6, 0 (worst) to 48 (best) for TOTPAR12, 0 (worst) to 96 (best) for TOTPAR24 and 0 (worst) to 192 (best) for TOTPAR48.

    Time frame: Hour 6, 12, 24, 48

  3. Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID)

    The SPRID is sum of SPID and TOTPAR. In SPID, PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<= 3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. In TOTPAR, pain relief score ranges from 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). Total score ranges from -18 (worst) to 42 (best) for SPRID6, -36 (worst) to 84 (best) for SPRID12, -72 (worst) to 168 (best) for SPRID24 and -144 (worst) to 336 (best) for SPRID48.

    Time frame: Hour 6, 12, 24, 48

  4. Time to the First Rescue Medication Administered Because of Insufficient Pain Relief

    The time until administration of the first rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief after administration of the study drug was recorded. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular \[directly into muscle\] or intravenous injection \[directly into vein\]).

    Time frame: Baseline up to Day 3

  5. Number of Doses of Rescue Medication Administered Because of Insufficient Pain Relief

    The frequency of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).

    Time frame: Baseline up to Day 3

  6. Dosage of Rescue Medication Administered Because of Insufficient Pain Relief

    The dosage of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).

    Time frame: Baseline up to Day 3

  7. Patient Global Impression of Change (PGIC) Score

    The PGIC was used to assess the degree of participant's overall improvement with treatment, and participants were instructed to assess how much the overall status had been improved after investigational product administration compared to baseline in 7 grades (1=Very much improved and B=Very much worsened).

    Time frame: Day 3

07

Results

Posted Jun 20, 2013

Participant flow

Participant flow — Overall Study
MilestoneTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Started162158
Completed116128
Not completed4630
Withdrew: Adverse event165
Withdrew: Withdrawal by subject2016
Withdrew: Protocol violation55
Withdrew: Physician decision31
Withdrew: Screening failure (drop-out)03
Withdrew: Other20

Outcome measures

PrimarySum of Pain Intensity Difference (SPID) at Hour 48

The SPID is time-weighted sum of all observations of pain intensity difference (PID) collected at each measurement time point from Baseline to 48 hours. PID: Baseline pain intensity (PI) minus current PI; PI was assessed using 11-point numeric rating scale (NRS, 0=no pain to 10=worst pain imaginable). PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score for SPID at 48 hours (SPID48) ranges from -144 (worst) to 144 (best).

Time frame:
Hour 48
Reported as:
Mean · Units on scale
Sum of Pain Intensity Difference (SPID) at Hour 48
Units on scaleTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Sum of Pain Intensity Difference (SPID) at Hour 4832.5 ± 30.737.2 ± 23.9
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.1648 (Hour 48: P-value was calculated using Student's t-test) · Mean difference (final values): -4.68 · 95% CI -11.29 to 1.93
SecondarySum of Pain Intensity Difference (SPID) at Hour 6, 12 and 24

The SPID is time-weighted sum of all observations of PID collected at each measurement time point from Baseline to 24 hours. PID: Baseline PI minus current PI; PI was assessed using 11-point NRS, 0=no pain to 10=worst pain imaginable. PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score ranges from -18 (worst) to 18 (best) for SPID6, -36 (worst) to 36 (best) for SPID12 and -72 (worst) to 72 (best) for SPID24.

Time frame:
Hour 6, 12, 24
Reported as:
Mean · Units on scale
Sum of Pain Intensity Difference (SPID) at Hour 6, 12 and 24
Units on scaleTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Hour 63.6 ± 3.73.9 ± 3.3
Hour 127.0 ± 7.88.1 ± 6.5
Hour 2414.6 ± 15.317.6 ± 12.7
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.4082 (Hour 6: P-value was calculated using Student's t-test) · Mean difference (final values): -0.32 · 95% CI -1.10 to 0.45
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.1720 (Hour 12: P-value was calculated using Student's t-test) · Mean difference (final values): -1.10 · 95% CI -2.68 to 0.48
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.0589 (Hour 24: P-value was calculated using Student's t-test) · Mean difference (final values): -2.99 · 95% CI -6.09 to 0.11
SecondaryTotal Pain Relief (TOTPAR) Score

Pain relief was measured on a 5-point categorical scale of 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). TOTPAR was calculated as the time-weighted sum over all pain relief up to 48 hours. Total score ranges from 0 (worst) to 24 (best) for TOTPAR6, 0 (worst) to 48 (best) for TOTPAR12, 0 (worst) to 96 (best) for TOTPAR24 and 0 (worst) to 192 (best) for TOTPAR48.

Time frame:
Hour 6, 12, 24, 48
Reported as:
Mean · Units on scale
Total Pain Relief (TOTPAR) Score
Units on scaleTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Hour 66.0 ± 4.86.8 ± 5.7
Hour 1212.5 ± 10.414.7 ± 11.1
Hour 2427.1 ± 21.331.0 ± 22.5
Hour 4855.6 ± 43.261.7 ± 44.5
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.1542 (Hour 6: P-value was calculated using Student's t-test)
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.0714 (Hour 12: P-value was calculated using Student's t-test)
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.1147 (Hour 24: P-value was calculated using Student's t-test)
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.2209 (Hour 48: P-value was calculated using Student's t-test)
SecondarySum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID)

The SPRID is sum of SPID and TOTPAR. In SPID, PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<= 3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. In TOTPAR, pain relief score ranges from 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). Total score ranges from -18 (worst) to 42 (best) for SPRID6, -36 (worst) to 84 (best) for SPRID12, -72 (worst) to 168 (best) for SPRID24 and -144 (worst) to 336 (best) for SPRID48.

Time frame:
Hour 6, 12, 24, 48
Reported as:
Mean · Units on scale
Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID)
Units on scaleTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Hour 69.6 ± 7.310.9 ± 8.1
Hour 1219.6 ± 15.723.1 ± 15.2
Hour 2441.8 ± 31.649.1 ± 30.8
Hour 4885.9 ± 64.797.0 ± 61.0
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.1498 (Hour 6: P-value was calculated using Student's t-test)
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.0485 (Hour 12: P-value was calculated using Student's t-test)
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.0404 (Hour 24: P-value was calculated using Student's t-test)
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.1210 (Hour 48: P-value was calculated using Student's t-test)
SecondaryTime to the First Rescue Medication Administered Because of Insufficient Pain Relief

The time until administration of the first rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief after administration of the study drug was recorded. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular \[directly into muscle\] or intravenous injection \[directly into vein\]).

Time frame:
Baseline up to Day 3
Reported as:
Mean · Minutes
Time to the First Rescue Medication Administered Because of Insufficient Pain Relief
MinutesTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Time to the First Rescue Medication Administered Because of Insufficient Pain Relief1339 ± 7101212 ± 853
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Wilcoxon (Mann-Whitney) · p = 0.4216 (P-value was calculated using Mann-Whitney's U test.)
SecondaryNumber of Doses of Rescue Medication Administered Because of Insufficient Pain Relief

The frequency of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).

Time frame:
Baseline up to Day 3
Reported as:
Mean · Doses
Number of Doses of Rescue Medication Administered Because of Insufficient Pain Relief
DosesTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Number of Doses of Rescue Medication Administered Because of Insufficient Pain Relief2.1 ± 1.91.4 ± 0.9
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Wilcoxon (Mann-Whitney) · p = 0.1000 (P-value was calculated using Mann-Whitney's U test.)
SecondaryDosage of Rescue Medication Administered Because of Insufficient Pain Relief

The dosage of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).

Time frame:
Baseline up to Day 3
Reported as:
Mean · Milligram
Dosage of Rescue Medication Administered Because of Insufficient Pain Relief
MilligramTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Dosage of Rescue Medication Administered Because of Insufficient Pain Relief50.0 ± 0.051.7 ± 9.1
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Wilcoxon (Mann-Whitney) · p = 0.3255 (P-value was calculated using Mann-Whitney's U test.)
SecondaryPatient Global Impression of Change (PGIC) Score

The PGIC was used to assess the degree of participant's overall improvement with treatment, and participants were instructed to assess how much the overall status had been improved after investigational product administration compared to baseline in 7 grades (1=Very much improved and B=Very much worsened).

Time frame:
Day 3
Reported as:
Mean · Units on scale
Patient Global Impression of Change (PGIC) Score
Units on scaleTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Patient Global Impression of Change (PGIC) Score2.71 ± 0.862.60 ± 0.80
Statistical analysis
  • Tramadol Hydrochloride (HCl)/Acetaminophen ER vs Tramadol HCl/Acetaminophen IR · Student's t-test · p = 0.2848 (Day 3: P-value was calculated using student's t-test)

Adverse events

Collected over Screening up to Day 3 or early withdrawal. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol Hydrochloride (HCl)/Acetaminophen ER—1/161 (0.6%)139/161 (86.3%)
Tramadol HCl/Acetaminophen IR—0/153 (0%)129/153 (84.3%)
Most frequent serious events
Most frequent serious events
EventTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
Deep vein thrombosisVascular disorders1/1610/153
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IR
NauseaGastrointestinal disorders80/16168/153
VomitingGastrointestinal disorders45/16137/153
Haemoglobin decreasedInvestigations38/16140/153
ConstipationGastrointestinal disorders39/16130/153
PyrexiaGeneral disorders28/16136/153
PruritusSkin and subcutaneous tissue disorders33/16126/153
DysuriaRenal and urinary disorders27/16124/153
DyspepsiaGastrointestinal disorders11/16120/153
DizzinessNervous system disorders17/16113/153
HeadacheNervous system disorders15/1619/153

Baseline characteristics

Age Continuous
Age Continuous(Years)Tramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IRTotal
Mean66.8 ± 6.467.5 ± 6.667.1 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)Tramadol Hydrochloride (HCl)/Acetaminophen ERTramadol HCl/Acetaminophen IRTotal
Female155138293
Male72027
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Park YB, Ha CW, Cho SD, Lee MC, Lee JH, Seo SS, Kang SB, Kyung HS, Choi CH, Chang N, Rhim HY, Bin SI. A randomized study to compare the efficacy and safety of extended-release and immediate-release tramadol HCl/acetaminophen in patients with acute pain following total knee replacement. Curr Med Res Opin. 2015 Jan;31(1):75-84. doi: 10.1185/03007995.2014.975338. Epub 2014 Oct 31. PubMed 25299350 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jan 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2013
First posted
Mar 20, 2013
Start
Nov 2009
Primary completionActual
Jan 2011
CompletionActual
Feb 2011
Results first posted
Jun 20, 2013
Last update
Jun 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01814878
Responsible party
Sponsor
First posted
Mar 20, 2013
Start date
Nov 2009
Primary completion
Jan 2011
Completion
Feb 2011
Results posted
Jun 20, 2013
Last update
Jun 20, 2013

Study contacts

Janssen Korea Ltd. Clinical Trial
study director · Janssen Korea Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion